ATOS
ATOSSA THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$2.56
−12.03%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -31.5%
- EBIT
- -30.9%
- EPS
- -28.7%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +31.8%
Three-year CAGR
- Revenue
- —
- EBITDA
- -36.4%
- EBIT
- -34.5%
- Net income
- -36.3%
- EPS
- -34.7%
- Free cash flow
- -41.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026